Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing

Cervical cancer is the fourth most frequently occurring cancer in women around the world and can affect them during their reproductive years. Since the development of the Papanicolaou (Pap) test, screening has been essential in identifying cervical cancer at a treatable stage. With the identificatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chrysostomou, Andreas C., Stylianou, Dora C., Constantinidou, Anastasia, Kostrikis, Leondios G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315375/
https://www.ncbi.nlm.nih.gov/pubmed/30572620
http://dx.doi.org/10.3390/v10120729
_version_ 1783384279467687936
author Chrysostomou, Andreas C.
Stylianou, Dora C.
Constantinidou, Anastasia
Kostrikis, Leondios G.
author_facet Chrysostomou, Andreas C.
Stylianou, Dora C.
Constantinidou, Anastasia
Kostrikis, Leondios G.
author_sort Chrysostomou, Andreas C.
collection PubMed
description Cervical cancer is the fourth most frequently occurring cancer in women around the world and can affect them during their reproductive years. Since the development of the Papanicolaou (Pap) test, screening has been essential in identifying cervical cancer at a treatable stage. With the identification of the human papillomavirus (HPV) as the causative agent of essentially all cervical cancer cases, HPV molecular screening tests and HPV vaccines for primary prevention against the virus have been developed. Accordingly, comparative studies were designed to assess the performance of cervical cancer screening methods in order to devise the best screening strategy possible. This review critically assesses the current cervical cancer screening methods as well as the implementation of HPV vaccination in Europe. The most recent European Guidelines and recommendations for organized population-based programs with HPV testing as the primary screening method are also presented. Lastly, the current landscape of cervical cancer screening programs is assessed for both European Union member states and some associated countries, in regard to the transition towards population-based screening programs with primary HPV testing.
format Online
Article
Text
id pubmed-6315375
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63153752019-01-10 Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing Chrysostomou, Andreas C. Stylianou, Dora C. Constantinidou, Anastasia Kostrikis, Leondios G. Viruses Review Cervical cancer is the fourth most frequently occurring cancer in women around the world and can affect them during their reproductive years. Since the development of the Papanicolaou (Pap) test, screening has been essential in identifying cervical cancer at a treatable stage. With the identification of the human papillomavirus (HPV) as the causative agent of essentially all cervical cancer cases, HPV molecular screening tests and HPV vaccines for primary prevention against the virus have been developed. Accordingly, comparative studies were designed to assess the performance of cervical cancer screening methods in order to devise the best screening strategy possible. This review critically assesses the current cervical cancer screening methods as well as the implementation of HPV vaccination in Europe. The most recent European Guidelines and recommendations for organized population-based programs with HPV testing as the primary screening method are also presented. Lastly, the current landscape of cervical cancer screening programs is assessed for both European Union member states and some associated countries, in regard to the transition towards population-based screening programs with primary HPV testing. MDPI 2018-12-19 /pmc/articles/PMC6315375/ /pubmed/30572620 http://dx.doi.org/10.3390/v10120729 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chrysostomou, Andreas C.
Stylianou, Dora C.
Constantinidou, Anastasia
Kostrikis, Leondios G.
Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing
title Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing
title_full Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing
title_fullStr Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing
title_full_unstemmed Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing
title_short Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing
title_sort cervical cancer screening programs in europe: the transition towards hpv vaccination and population-based hpv testing
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315375/
https://www.ncbi.nlm.nih.gov/pubmed/30572620
http://dx.doi.org/10.3390/v10120729
work_keys_str_mv AT chrysostomouandreasc cervicalcancerscreeningprogramsineuropethetransitiontowardshpvvaccinationandpopulationbasedhpvtesting
AT stylianoudorac cervicalcancerscreeningprogramsineuropethetransitiontowardshpvvaccinationandpopulationbasedhpvtesting
AT constantinidouanastasia cervicalcancerscreeningprogramsineuropethetransitiontowardshpvvaccinationandpopulationbasedhpvtesting
AT kostrikisleondiosg cervicalcancerscreeningprogramsineuropethetransitiontowardshpvvaccinationandpopulationbasedhpvtesting